MX2021014918A - Derivados de 3-(2-(heteroaril)-piridin-4-yl)-5-(trifluorometil)-1, 2,4-oxadiazol como inhibidores de hdac6. - Google Patents

Derivados de 3-(2-(heteroaril)-piridin-4-yl)-5-(trifluorometil)-1, 2,4-oxadiazol como inhibidores de hdac6.

Info

Publication number
MX2021014918A
MX2021014918A MX2021014918A MX2021014918A MX2021014918A MX 2021014918 A MX2021014918 A MX 2021014918A MX 2021014918 A MX2021014918 A MX 2021014918A MX 2021014918 A MX2021014918 A MX 2021014918A MX 2021014918 A MX2021014918 A MX 2021014918A
Authority
MX
Mexico
Prior art keywords
pyridin
heteroaryl
trifluoromethyl
hdac6 inhibitors
zole derivatives
Prior art date
Application number
MX2021014918A
Other languages
English (en)
Spanish (es)
Inventor
González Elena Carceller
Solana Jorge Salas
Muñoz Alberto Ortega
Original Assignee
Oryzon Genomics Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oryzon Genomics Sa filed Critical Oryzon Genomics Sa
Publication of MX2021014918A publication Critical patent/MX2021014918A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2021014918A 2019-06-06 2020-06-05 Derivados de 3-(2-(heteroaril)-piridin-4-yl)-5-(trifluorometil)-1, 2,4-oxadiazol como inhibidores de hdac6. MX2021014918A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19382475 2019-06-06
EP19383221 2019-12-31
PCT/EP2020/065658 WO2020245381A1 (en) 2019-06-06 2020-06-05 3-(2-(heteroaryl)-pyridin-4-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole derivatives as hdac6 inhibitors

Publications (1)

Publication Number Publication Date
MX2021014918A true MX2021014918A (es) 2022-06-27

Family

ID=71083614

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021014918A MX2021014918A (es) 2019-06-06 2020-06-05 Derivados de 3-(2-(heteroaril)-piridin-4-yl)-5-(trifluorometil)-1, 2,4-oxadiazol como inhibidores de hdac6.

Country Status (7)

Country Link
US (1) US12522598B2 (https=)
EP (1) EP3980416B1 (https=)
JP (1) JP7523146B2 (https=)
CN (1) CN114206868B (https=)
CA (1) CA3142435A1 (https=)
MX (1) MX2021014918A (https=)
WO (1) WO2020245381A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
AU2020321955A1 (en) 2019-07-30 2022-03-17 Eikonizo Therapapeutics, Inc. HDAC6 inhibitors and uses thereof
TW202345813A (zh) 2022-04-08 2023-12-01 美商艾科尼佐療法股份有限公司 㗁二唑ｈｄａｃ６抑制劑及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8101618B2 (en) 2005-04-06 2012-01-24 Msd K.K. 1,4-substituted piperazine derivatives
US20100136024A1 (en) 2008-11-14 2010-06-03 Bartels Stephen P Selective Inhibition of Histone Deacetylase 6 for Ocular Neuroprotection or for Treatment or Control of Glaucoma
NZ610225A (en) 2010-11-16 2015-08-28 Acetylon Pharmaceuticals Inc Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof
WO2013066839A2 (en) 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods
BR112014012815A8 (pt) 2011-11-28 2017-06-20 Novartis Ag derivados de trifluormetil-oxadiazol e uso dos mesmos no tratamento de doença
US10081624B2 (en) 2014-08-26 2018-09-25 Takeda Pharmaceutical Company Limited Heterocyclic compound
JPWO2017014170A1 (ja) 2015-07-17 2018-04-26 武田薬品工業株式会社 複素環化合物
AU2016297362B2 (en) 2015-07-17 2020-04-16 Takeda Pharmaceutical Company Limited Oxadiazole derivatives useful as HDAC inhibitors
WO2017033946A1 (ja) 2015-08-25 2017-03-02 武田薬品工業株式会社 複素環化合物
WO2017161033A1 (en) 2016-03-15 2017-09-21 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
WO2017222952A1 (en) * 2016-06-23 2017-12-28 Merck Sharp & Dohme Corp. 3- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
WO2017222951A1 (en) * 2016-06-23 2017-12-28 Merck Sharp & Dohme Corp. 3-aryl and heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
WO2017222950A1 (en) 2016-06-23 2017-12-28 Merck Sharp & Dohme Corp. 3-heterocyclyl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
WO2018118781A1 (en) 2016-12-20 2018-06-28 Fmc Corporation Fungicidal oxadiazoles
SG11202005254RA (en) * 2017-12-05 2020-07-29 Oryzon Genomics Sa 1,2,4-oxadiazole derivatives as histone deacetylase 6 inhibitors

Also Published As

Publication number Publication date
US12522598B2 (en) 2026-01-13
CN114206868B (zh) 2025-02-25
WO2020245381A1 (en) 2020-12-10
JP2022535290A (ja) 2022-08-05
CN114206868A (zh) 2022-03-18
JP7523146B2 (ja) 2024-07-26
EP3980416A1 (en) 2022-04-13
US20220298156A1 (en) 2022-09-22
CA3142435A1 (en) 2020-12-10
EP3980416B1 (en) 2026-03-11

Similar Documents

Publication Publication Date Title
ZA202004023B (en) 1,2,4-oxadiazole derivatives as histone deacetylase 6 inhibitors
CL2018003290A1 (es) Amidas heterocíclicas útiles como moduladores de proteínas (divisional de solicitud cl 2850-2018).
EP4501932A3 (en) Kras g12c inhibitors
DK3976604T3 (da) 1,3,4-oxadiazol-derivatforbindelser som histondeacetylase 6-hæmmer og den farmaceutiske sammensætning, der omfatter den samme
SA519410865B1 (ar) مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه
EP4302834A3 (en) 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
BR112018072542A2 (pt) derivados de piridiniltriazol substituído com amida e usos dos mesmos
IL288508A (en) History of n-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylsulfonamido)pyrimidin-4-yl)tetrahydro-h2-pyran-4-carboxamide and related compounds as human ctps1 inhibitors to treat proliferative diseases
EP3753943A4 (en) HETEROCYCLIC COMPOUND, ITS APPLICATION AND PHARMACEUTICAL COMPOSITION CONSISTING OF IT
EP3569601A3 (en) N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
HUE063879T2 (hu) 4-(l,3,4-oxadiazol-2-il)piridin-2(lH)-on származékok mint hiszton-deacetiláz 6 (HDAC6) inhibitorok például a fertõzések kezelésében
MX2024001849A (es) Antagonista del receptor del factor de liberacion de corticotropina 1 (crf1), formulaciones farmaceuticas y formas solidas del mismo para el tratamiento de hiperplasia suprarrenal congenita.
MY198769A (en) Substituted heterocyclic derivatives as cdk inhibitors
MA55571A (fr) Compositions pharmaceutiques comprenant n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
EA201000774A1 (ru) Ингибиторы бета-лактамазы
NZ700761A (en) Salt form of a human histone methyltransferase ezh2 inhibitor
JOP20170104A1 (ar) مشتقات فنيل تريازول مستبدلة بأميد واستخدامها
MX2021014918A (es) Derivados de 3-(2-(heteroaril)-piridin-4-yl)-5-(trifluorometil)-1, 2,4-oxadiazol como inhibidores de hdac6.
MX2021001807A (es) Combinacion de un inhibidor de histona desacetilasa y un inhibidor de proteina cinasa y uso farmaceutico de la misma.
EP4442318A3 (en) Heterocyclic inhibitors of mct4
EP3845528C0 (en) PYRAZOLE COMPOUNDS, CORRESPONDING PHARMACEUTICAL COMPOSITIONS AND USE THEREOF AS IRAK4 INHIBITORS
EP3976602A4 (en) 1,3,4-OXADIAZOLE HOMOPHTHALIMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE-6 INHIBITOR AND PHARMACEUTICAL COMPOSITION THEREOF
MX2023009388A (es) Metodos para tratar alteraciones del comportamiento.
PH12017501933A1 (en) Bromodomain inhibitor